Download
akmatov1.pdf 684,64KB
WeightNameValue
1000 Titel
  • Anti-nuclear autoantibodies in the general German population: Prevalence and lack of association with selected cardiovascular and metabolic disorders—findings of a multicenter population-based study
1000 Autor/in
  1. Akmatov, Manas K |
  2. Röber, Nadja |
  3. Flesch-Janys, Dieter |
  4. Fricke, Julia |
  5. Greiser, Halina |
  6. Günther, Kathrin |
  7. Kaaks, Rudolf |
  8. Kemmling, Yvonne |
  9. Krone, Bastian |
  10. Linseisen, Jakob |
  11. Meisinger, Christa |
  12. Moebus, Susanne |
  13. Obi, Nadia |
  14. Guzman, Carlos A |
  15. Conrad, Karsten |
  16. Pessler, Frank |
  17. Ahrens, Wolfgang |
1000 Erscheinungsjahr 2017
1000 Art der Datei
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2017-06-06
1000 Erschienen in
1000 Quellenangabe
  • 19:127
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2017
1000 Lizenz
1000 Verlagsversion
  • http://dx.doi.org/10.1186/s13075-017-1338-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461675/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: We determined the prevalence of anti-nuclear autoantibodies (ANAs) in the German adult population and examined the association between ANAs and cardiovascular and metabolic disorders. METHODS: We used data and blood samples from the pretest phases of the German National Cohort, obtained from six of the 18 study centers (n = 1199). All centers applied standardized instruments including face-to-face interviews, anthropometric measurements and collection of blood samples. Self-reported histories of diabetes mellitus, heart attack and elevated blood cholesterol and/or lipids were recorded. Height, weight and blood pressure were measured. ANAs were detected using a semi-automated system (AKLIDES®; Medipan GmbH, Dahlewitz, Germany). A positive ANA was defined as a titer ≥ 1:80. ANA were classified as weakly (1:80 or 1:160), moderately (1:320 or 1:640) or strongly (≥1:1280) positive. Specific autoantibodies against nuclear antigens were detected with second-step assays according to the ANA staining pattern. Associations between the assessed disorders and ANA positivity and pattern were examined using sex and age-adjusted mixed-effects logistic regression models. RESULTS: Thirty-three percent (95% confidence interval; 31–36%) of the 1196 participants (measurements could not be obtained from three samples) were ANA positive (titer ≥ 1:80). The proportions of weakly, moderately and strongly positive ANA were 29%, 3.3% and 1.3%, respectively. ANA positivity was more common among women than men across all titers (χ(2), p = 0.03). ANA positivity, even when stratified according to height of titer or immunofluorescent pattern, was not associated with diabetes, elevated blood cholesterol and/or lipids, obesity or hypertension. Second-step autoantibody assays were positive in 41 of the 83 samples (49%) tested, with anti-DFS70 (n = 13) and anti-dsDNA (n = 7) being most frequent. These subgroups were too small to test for associations with the disorders assessed. CONCLUSIONS: The prevalence of ANA positivity in the German general population was similar to values reported from other countries. Contrary to other studies, there was no association with selected self-reported and objectively measured cardiovascular and metabolic variables.
1000 Sacherschließung
lokal anti-nuclear autoantibodies
lokal German National Cohort
lokal population-based study
lokal metabolism
lokal diabetes
lokal hypertension
lokal obesity
1000 Fachgruppe
  1. Medizin |
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/QWttYXRvdiwgTWFuYXMgSw==|https://frl.publisso.de/adhoc/creator/UsO2YmVyLCBOYWRqYQ==|https://frl.publisso.de/adhoc/creator/Rmxlc2NoLUphbnlzLCBEaWV0ZXI=|https://frl.publisso.de/adhoc/creator/RnJpY2tlLCBKdWxpYQ==|https://frl.publisso.de/adhoc/creator/R3JlaXNlciwgSGFsaW5h|https://frl.publisso.de/adhoc/creator/R8O8bnRoZXIsIEthdGhyaW4=|https://frl.publisso.de/adhoc/creator/S2Fha3MsIFJ1ZG9sZg==|https://frl.publisso.de/adhoc/creator/S2VtbWxpbmcsIFl2b25uZQ==|https://frl.publisso.de/adhoc/creator/S3JvbmUsIEJhc3RpYW4=|https://frl.publisso.de/adhoc/creator/TGluc2Vpc2VuLCBKYWtvYg==|https://frl.publisso.de/adhoc/creator/TWVpc2luZ2VyLCBDaHJpc3Rh|https://frl.publisso.de/adhoc/creator/TW9lYnVzLCBTdXNhbm5l|https://frl.publisso.de/adhoc/creator/T2JpLCBOYWRpYQ==|https://frl.publisso.de/adhoc/creator/R3V6bWFuLCBDYXJsb3MgQQ==|https://frl.publisso.de/adhoc/creator/Q29ucmFkLCBLYXJzdGVu|https://frl.publisso.de/adhoc/creator/UGVzc2xlciwgRnJhbms=|http://orcid.org/0000-0003-3777-570X
1000 Fördernummer
  1. 01ER1001A-I
1000 Förderprogramm
  1. -
  2. Portfolio Topic “Metabolic Dysfunction and Chronic Disease”; iMed—the Helmholtz Association’s Initiative on Personalized Medicine
  3. -
  4. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6404590.rdf
1000 Erstellt am 2017-09-22T12:14:49.194+0200
1000 Erstellt von 122
1000 beschreibt frl:6404590
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet Mon Apr 30 14:04:22 CEST 2018
1000 Objekt bearb. Mon Apr 30 14:04:22 CEST 2018
1000 Vgl. frl:6404590
1000 Oai Id
  1. oai:frl.publisso.de:frl:6404590 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source